New data show ReNeuron’s lead CTX cell therapy candidate can be
re-programmed into a pluripotent state and differentiated into other cell types
These new cell types can be efficiently expanded as potential cell therapy candidates targeting a broad range of diseases
23 October 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that new data relating to its CTX stem cell platform will be presented today at the 27th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), a leading scientific conference taking place this week in Barcelona, Spain.